We have also shown that forced expression of PODXL in Raji Burkitt lymphoma cells increased cell survival upon treatment with obinutuzumab [27], a novel type II glycoengineered humanized anti-CD20 monoclonal antibody with superior ability to induce direct, non-complement dependent cell death and enhanced antibody-dependent cellular cytotoxicity (ADCC) compared to rituximab [124,125]. Here, PODXL is linked to Burkitt lymphoma.